Cardiovascular diseases are the number one cause of mortality in developed countries. A European study explored the feasibility of improving the vascularisation of infarcted myocardium through the transplantation of differentiated cells obtained from stem cells.
Human embryonic stem cells (hESCs) constitute an unlimited source for production of desired cell types including cardiomyocytes, through controlled differentiation. This renders them an invaluable tool for regenerative medicine applications.